导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.02% | 1484/4762 |
| 近一周 | -1.19% | 1782/5451 |
| 近一月 | -8.27% | 4859/5408 |
| 近一季 | -18.31% | 4719/5218 |
| 近半年 | -0.37% | 1460/4907 |
| 近一年 | 8.09% | 1376/4387 |
| 近两年 | 115.26% | 471/2950 |
| 近三年 | 70.84% | 339/2249 |
| 成立以来 | 83.45% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.72% 1924/4961 |
35.31% 916/5312 |
- - |
- - |
| 2025 | 49.96% 471/4813 |
-1.22% 2609/3635 |
3.33% 1049/4076 |
48.03% 406/4524 |
-0.75% 2627/4813 |
| 2024 | 15.47% 924/3463 |
-3.30% 1486/2808 |
-5.99% 1828/3014 |
27.45% 222/3129 |
-0.34% 1389/3463 |
| 2023 | -15.85% 1661/2656 |
4.17% 1030/2280 |
-6.93% 1742/2385 |
-8.45% 1701/2515 |
-5.20% 1287/2655 |
| 2022 | -26.31% 1389/2207 |
-18.91% 1412/1919 |
5.42% 901/2016 |
-16.88% 1516/2113 |
3.71% 655/2208 |
| 2021 | 16.72% 260/1822 |
-5.32% 914/1255 |
26.17% 79/1330 |
-5.04% 767/1466 |
2.89% 502/1822 |
| 2020 | 65.25% 95/1250 |
3.48% 118/1028 |
29.05% 86/1067 |
5.95% 887/1164 |
16.79% 152/1184 |
| 2019 | 43.49% 191/1092 |
33.56% 136/754 |
-9.17% 637/804 |
7.36% 91/850 |
10.17% 156/918 |
| 2018 | -26.15% 372/834 |
- - |
- - |
- - |
-11.28% 278/691 |
| 2017 | -11.43% 545/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国泰创业板指数(LOF)A VS. 长安沪深300非周期A(740101) |